M. F. OZCAN Et Al. , "Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy," UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.31, no.8, pp.1709-1715, 2013
OZCAN, M. F. Et Al. 2013. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.31, no.8 , 1709-1715.
OZCAN, M. F., Dizdar, O., DINCER, N., BALCI, S., Guler, G., GOK, B., ... PEKTAS, G.(2013). Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.31, no.8, 1709-1715.
OZCAN, Muhammet Et Al. "Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy," UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.31, no.8, 1709-1715, 2013
OZCAN, Muhammet F. Et Al. "Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy." UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.31, no.8, pp.1709-1715, 2013
OZCAN, M. F. Et Al. (2013) . "Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy." UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS , vol.31, no.8, pp.1709-1715.
@article{article, author={Muhammet Fuat OZCAN Et Al. }, title={Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy}, journal={UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS}, year=2013, pages={1709-1715} }